In a specialized session held on September 27, 2025, the revised feasibility study for the Plasma Investment Project was reviewed by senior officials of the Medical Procurement Organization, leading plasma experts, and the Managing Director of Helal Iran Medical Devices Company. It was agreed that the final version of the proposal, incorporating expert revisions, will be presented at the upcoming session for executive decision-making.
According to the Public Relations and
International Affairs Unit of the Medical Procurement Organization, the session
was chaired by Dr. Mohammadreza Shanehsaz, Managing Director of the
Organization, and attended by senior executives, domain specialists, and Dr.
Sobhani, Managing Director of Helal Iran Medical Devices Company.
During the meeting, Dr. Sobhani, as
the project lead, presented the revised feasibility study. The updated version
aims to enhance operational precision, ensure compliance with regulatory
requirements, and optimize technical infrastructure. Following expert
deliberations and the exchange of professional insights, the session concluded
with a directive from the Managing Director to expedite the implementation
process. It was resolved that the final version of the proposal, reflecting the
necessary amendments, will be submitted next week for final approval.
The Plasma Investment Project is
considered one of the strategic initiatives of the Medical Procurement
Organization, designed to expand national capacity in blood-derived products.
The project seeks to strengthen the country’s healthcare infrastructure, ensure
sustainable supply of plasma-based therapies, and advance national capabilities
in the health sector.